Erythrodermic mycosis fungoides and Sézary syndrome are chronic, relapsing-remitting diseases that greatly impacts patients' quality of life (QoL). Mogamulizumab-kpkc (Mogamulizumab) is a novel therapeutic agent for cutaneous T-cell lymphomas with a notable impact on progression-free survival. Qualitative assessment methods allow a broader exploration and greater insight in individual patient experience than quantitative studies. However, there is limited data on the impact of mogamulizumab on health-related QoL. To investigate the impact of erythrodermic cutaneous T-cell lymphoma (E-CTCL) on QoL and the effect of mogamulizumab on the QoL. Semi-structured interview were conducted with seven patients with E-CTCL that were receiving mogamulizumab treatment. Five major themes arose: Diagnosis and the diagnostic delay and uncertainty experienced by participants; Physical functioning due to the high symptom burden; Psychological and social functioning considering the significant impact on daily life; Treatment and the effect of mogamulizumab; and Support by family, friends and health professionals. Mogamulizumab therapy resulted in a significant decrease of symptoms. The small sample size should also be taken into account although data saturation was reached. This study gives a broad insight into the large impact of E-CTCL and the major consequences on the physical functioning as well as on the emotional/psychological and social well-being. Mogamulizumab appears to have a positive effect on symptoms.
Journal Article Accepted manuscript Cutaneous T-cell lymphoma in Australia: what drives geospatial? Get access Rosanne Ottevanger, Rosanne Ottevanger Department of dermatology, Leiden University Medical Centre, Leiden, The Netherlands Search for other works by this author on: Oxford Academic Google Scholar Maarten H Vermeer Maarten H Vermeer Department of dermatology, Leiden University Medical Centre, Leiden, The Netherlands Correspondence: Maarten H. Vermeer, Email:[email protected] https://orcid.org/0000-0002-5872-4613 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljaf026, https://doi.org/10.1093/bjd/ljaf026 Published: 22 February 2025 Article history Received: 10 January 2025 Accepted: 13 January 2025 Published: 22 February 2025
To the Editor: First of all, we thank Joshi and Duvic1Joshi T.P. Duvic M. Understanding itch in cutaneous T cell lymphoma: exploring the impact of comorbidities, treatment regimens, and racial differences on quality of life.JAAD Int. 2023; 10: 55-56Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar for their critical review and reaction of our paper regarding itching and the quality of life (QoL) in patients with cutaneous T-cell lymphoma.2Ottevanger R. van Beugen S. Evers A.W.M. Willemze R. Vermeer M.H. Quint K.D. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator.JAAD Int. 2022; 9: 57-64Abstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar This will help us to gain more attention for this underexposed subject in cutaneous lymphoma research. Although we agree that the Charlson Comorbidity Index has its limitations since it only includes the most common and severe comorbidities, it is currently the most validated method of assessing comorbidities in QoL research.3Kobayashi Y. Miura K. Hojo A. et al.Charlson comorbidity index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma.J Cancer Res Clin Oncol. 2011; 137: 1079-1084Crossref PubMed Scopus (61) Google Scholar We are aware that other comorbidities may also occur and not all patients experience the comorbidities as the same burden. However, their example of vitiligo does not match with our experience. Given the similarities between vitiligo and hypopigmented mycosis fungoides, one wonders if this association may be due to misclassification of hypopigmented mycosis fungoides as vitiligo.4Kim J.C. Kim Y.C. Hypopigmented mycosis fungoides mimicking vitiligo.Am J Dermatopathol. 2021; 43: 213-216Crossref PubMed Scopus (5) Google Scholar The suggestion that vitiligo has a higher impact on QoL than other comorbidities is not substantiated by published reports and deserves further study.5Ottevanger R. van Beugen S. Evers A.W.M. Willemze R. Vermeer M.H. Quint K.D. Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature.J Eur Acad Dermatol Venereol. 2021; 35: 2377-2387Crossref PubMed Scopus (15) Google Scholar The treatment regimens of our patients were not included as part of the study as it does not directly affect the outcome. It is acknowledged that the type of treatment may affect QoL. However, drug-induced itch suppression will result in a better itch score and (itch-related) QoL. Patients in our cohort were not treated with histone deacetylase inhibitors, which are not registered on the Dutch medicine market, or extracorporeal photopheresis, and had not received total skin electron beam therapy recently. Recording ethnicity routinely is not allowed in the Netherlands, but Fitzpatrick skin types V and VI are estimated to represent <5% of Dutch patients with cutaneous T-cell lymphoma. Again, we thank Joshi and Duvic1Joshi T.P. Duvic M. Understanding itch in cutaneous T cell lymphoma: exploring the impact of comorbidities, treatment regimens, and racial differences on quality of life.JAAD Int. 2023; 10: 55-56Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar for their critical review and we wholeheartedly agree that better measuring tools are necessary. Future research indeed needs to focus on developing and validate dedicated tools for patients with cutaneous T-cell lymphoma to optimize QoL measurements for implementation in daily practice. None disclosed. Understanding itch in cutaneous T-cell lymphoma: Exploring the impact of comorbidities, treatment regimens, and racial differences on quality of lifeJAAD InternationalVol. 10PreviewTo the Editor: We read with interest the paper by Ottevanger et al,1 which explores the impact of itch on the quality of life (QoL) of patients with cutaneous T-cell lymphoma (CTCL). The investigators show pruritus to have a significant impact on the QoL of patients with CTCL. Importantly, the authors show more advanced CTCL to be associated with poorer QoL, extending our previous work on this topic.2 Here, we wish to point out some limitations of the study and highlight areas for further research. Full-Text PDF Open Access
The standard treatment for cutaneous squamous cell carcinoma (cSCC) is surgical excision. Failure to radically remove a cSCC is a risk for recurrence, progression and metastasis.This study investigates several risk factors for incomplete excision of cSCC.All consecutive patients in a single institution treated with wide local excision for primary cSCC over a 10-year period were included in this study. Risk factors such as: gender, age, immunosuppression, tumour size, location, differentiation grade, tumour depth, perineural and lymphovascular invasion (PNI and LVI) were extracted from the database. Univariable and (if applicable) multivariable logistic regression analysis were used to identify risk factors (P < 0.05). Generalized estimating equations (GEEs) were used for multiple tumours within the same patients.A total of 566 patients with 1159 cSCC were identified. Univariable and multivariable logistic regression analysis showed that depth beyond the dermis (OR: 5.7 95% CI: 3.1-10.5) was the only risk factor for incomplete excision of cSCC. Immunosuppression was only a risk factor in the deep plane (OR: 2.5, 95% CI: 1.3-4.6).Tumour depth beyond the dermis is the most important risk factor for incomplete excision of cSCC. Immunosuppression is a risk factor in the deep plane but its relevance is uncertain. Immunosuppression is not consistently included in the current cSCC staging systems, but care should be taken when treating these patients.
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
